 Life Science Events, Jobs, Directory, News  LEXINGTON, Mass.–(BUSINESS WIRE)—- $AGEN #AACR2026–Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that data from an investigator-initiated Phase II trial conducted at Memorial Sloan Kettering Cancer Center will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026, in San Diego, CA. The study evaluates botensilimab (BOT) and balstilimab (BAL) in combination with agenT-797, an allogeneic iNKT cell therapy developed
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. |